Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2017

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2017, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 70, 75, 5, 133, 25 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 14, 1, 24 and 6 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

2
Introduction 8
Multiple Myeloma (Kahler Disease) - Overview 9
Multiple Myeloma (Kahler Disease) - Therapeutics Development 10
Multiple Myeloma (Kahler Disease) - Therapeutics Assessment 55
Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development 81
Multiple Myeloma (Kahler Disease) - Drug Profiles 154
Multiple Myeloma (Kahler Disease) - Dormant Projects 1161
Multiple Myeloma (Kahler Disease) - Discontinued Products 1177
Multiple Myeloma (Kahler Disease) - Product Development Milestones 1180
Appendix 1189

List Of Tables

List of Tables
Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2017 46
Number of Products under Development by Companies, H2 2017 48
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 49
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 50
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 51
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 52
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 53
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 54
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 55
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 56
Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 57
Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 58
Number of Products under Development by Universities/Institutes, H2 2017 59
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 61
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 62
Products under Development by Companies, H2 2017 63
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 64
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 65
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 66
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 67
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 68
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 69
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 70
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 71
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 72
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 73
Products under Development by Companies, H2 2017 (Contd..11), H2 2017 74
Products under Development by Companies, H2 2017 (Contd..12), H2 2017 75
Products under Development by Companies, H2 2017 (Contd..13), H2 2017 76
Products under Development by Companies, H2 2017 (Contd..14), H2 2017 77
Products under Development by Companies, H2 2017 (Contd..15), H2 2017 78
Products under Development by Companies, H2 2017 (Contd..16), H2 2017 79
Products under Development by Companies, H2 2017 (Contd..17), H2 2017 80
Products under Development by Companies, H2 2017 (Contd..18), H2 2017 81
Products under Development by Companies, H2 2017 (Contd..19), H2 2017 82
Products under Development by Companies, H2 2017 (Contd..20), H2 2017 83
Products under Development by Companies, H2 2017 (Contd..21), H2 2017 84
Products under Development by Companies, H2 2017 (Contd..22), H2 2017 85
Products under Development by Companies, H2 2017 (Contd..23), H2 2017 86
Products under Development by Universities/Institutes, H2 2017 87
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 88
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 89
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 90
Number of Products by Stage and Target, H2 2017 92
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 93
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 94
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 95
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 96
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 97
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 98
Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 99
Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017 100
Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017 101
Number of Products by Stage and Mechanism of Action, H2 2017 103
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 104
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 105
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 106
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 107
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 108
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 109
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 110
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017 111
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017 112
Number of Products by Stage and Route of Administration, H2 2017 114
Number of Products by Stage and Molecule Type, H2 2017 116
Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2017 117
Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2017 118
Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H2 2017 118
Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2017 119
Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2017 119
Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2017 120
Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2017 120
Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2017 121
Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2017 121
Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H2 2017 121
Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H2 2017 122
Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2017 123
Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H2 2017 123
Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2017 124
Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics Inc, H2 2017 124
Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H2 2017 125
Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H2 2017 125
Multiple Myeloma (Kahler Disease) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 125
Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc, H2 2017 126
Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals Inc, H2 2017 126
Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2017 127
Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2017 127
Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 128
Multiple Myeloma (Kahler Disease) - Pipeline by Autolus Ltd, H2 2017 128
Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2017 129
Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 129
Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017 130
Multiple Myeloma (Kahler Disease) - Pipeline by Biomunex Pharmaceuticals, H2 2017 130
Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2017 131
Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H2 2017 131
Multiple Myeloma (Kahler Disease) - Pipeline by Boehringer Ingelheim GmbH, H2 2017 132
Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2017 132
Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Co, H2 2017 133
Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H2 2017 133
Multiple Myeloma (Kahler Disease) - Pipeline by CanBas Co Ltd, H2 2017 134
Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2017 135
Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2017 135
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H2 2017 136
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H2 2017 136
Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H2 2017 137
Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2017 137
Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2017 138
Multiple Myeloma (Kahler Disease) - Pipeline by Cellular Biomedicine Group Inc, H2 2017 138
Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2017 139
Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 139
Multiple Myeloma (Kahler Disease) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 140
Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2017 140
Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 141
Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 141
Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2017 142
Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Co, H2 2017 142
Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2017 142
Multiple Myeloma (Kahler Disease) - Pipeline by eTheRNA Immunotherapies NV, H2 2017 143
Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H2 2017 143
Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 144
Multiple Myeloma (Kahler Disease) - Pipeline by Five Prime Therapeutics Inc, H2 2017 144
Multiple Myeloma (Kahler Disease) - Pipeline by Galileo Research srl, H2 2017 145
Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H2 2017 145
Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H2 2017 146
Multiple Myeloma (Kahler Disease) - Pipeline by Genentech Inc, H2 2017 146
Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2017 147
Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 147
Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H2 2017 148
Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H2 2017 148
Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H2 2017 148
Multiple Myeloma (Kahler Disease) - Pipeline by GT Biopharma Inc, H2 2017 149
Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H2 2017 149
Multiple Myeloma (Kahler Disease) - Pipeline by HitGen LTD, H2 2017 150
Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2017 150
Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene Inc, H2 2017 150
Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2017 151
Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2017 152
Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2017 152
Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2017 153
Multiple Myeloma (Kahler Disease) - Pipeline by Istesso Ltd, H2 2017 153
Multiple Myeloma (Kahler Disease) - Pipeline by Janpix Inc, H2 2017 153
Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals LLC, H2 2017 154
Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2017 155
Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2017 155
Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2017 156
Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H2 2017 156
Multiple Myeloma (Kahler Disease) - Pipeline by Karus Therapeutics Ltd, H2 2017 157
Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2017 157
Multiple Myeloma (Kahler Disease) - Pipeline by Kite Pharma Inc, H2 2017 158
Multiple Myeloma (Kahler Disease) - Pipeline by Klyss Biotech Inc, H2 2017 158
Multiple Myeloma (Kahler Disease) - Pipeline by Leadiant Biosciences Inc, H2 2017 159
Multiple Myeloma (Kahler Disease) - Pipeline by Les Laboratoires Servier SAS, H2 2017 159
Multiple Myeloma (Kahler Disease) - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 159
Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2017 160
Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune LLC, H2 2017 160
Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2017 161
Multiple Myeloma (Kahler Disease) - Pipeline by Midatech Pharma US Inc, H2 2017 161
Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 162
Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2017 162
Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2017 163
Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2017 163
Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2017 164
Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2017 164
Multiple Myeloma (Kahler Disease) - Pipeline by NantKwest Inc, H2 2017 165
Multiple Myeloma (Kahler Disease) - Pipeline by NBE-Therapeutics AG, H2 2017 165
Multiple Myeloma (Kahler Disease) - Pipeline by Neonc Technologies Inc, H2 2017 165
Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2017 166
Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H2 2017 166
Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2017 167
Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2017 168
Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2017 168
Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2017 169
Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2017 169
Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2017 170
Multiple Myeloma (Kahler Disease) - Pipeline by OncoTartis Inc, H2 2017 170
Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 171
Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H2 2017 171
Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2017 172
Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2017 172
Multiple Myeloma (Kahler Disease) - Pipeline by Phosplatin Therapeutics LLC, H2 2017 173
Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd, H2 2017 173
Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2017 173
Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2017 174
Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2017 174
Multiple Myeloma (Kahler Disease) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 175
Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2017 175
Multiple Myeloma (Kahler Disease) - Pipeline by Samyang Biopharmaceuticals Corp, H2 2017 176
Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2017 176
Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2017 177
Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Life Sciences Group Ltd, H2 2017 177
Multiple Myeloma (Kahler Disease) - Pipeline by Selvita SA, H2 2017 178
Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2017 178
Multiple Myeloma (Kahler Disease) - Pipeline by Shuttle Pharmaceuticals LLC, H2 2017 178
Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H2 2017 179
Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017 180
Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2017 180
Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 181
Multiple Myeloma (Kahler Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 181
Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2017 181
Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2017 182
Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 182
Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 183
Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2017 183
Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2017 184
Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2017 184
Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H2 2017 184
Multiple Myeloma (Kahler Disease) - Pipeline by TRACON Pharmaceuticals Inc, H2 2017 185
Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals Inc, H2 2017 185
Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2017 186
Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2017 186
Multiple Myeloma (Kahler Disease) - Pipeline by TTY Biopharm Company Ltd, H2 2017 187
Multiple Myeloma (Kahler Disease) - Pipeline by Unum Therapeutics Inc, H2 2017 187
Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2017 187
Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2017 188
Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H2 2017 188
Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2017 189
Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd, H2 2017 189
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 1197
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..1), H2 2017 1198
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..2), H2 2017 1199
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..3), H2 2017 1200
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..4), H2 2017 1201
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..5), H2 2017 1202
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..6), H2 2017 1203
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..7), H2 2017 1204
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..8), H2 2017 1205
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..9), H2 2017 1206
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..10), H2 2017 1207
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..11), H2 2017 1208
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..12), H2 2017 1209
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..13), H2 2017 1210
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..14), H2 2017 1211
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..15), H2 2017 1212
Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2017 1213
Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2017 (Contd..1), H2 2017 1214
Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2017 (Contd..2), H2 2017 1215

Fill The Form For Sample Request

There is no Reviews available